Skip to main content
TipRanks
Go Ultimate75% OFF

Cognition Therapeutics (CGTX) Drug Pipeline

655 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Active Comparator Ct1812Age-Related Macular DegenerationPhase IITerminatedStudy to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).May 17, 2023―
Ct1812Early Alzheimer's DiseasePhase IIActive Not RecruitingA Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's DiseaseAug 08, 2022―
Ct1812Dementia With Lewy BodiesPhase IICompletedStudy to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy BodiesJan 11, 2022―
Ct1812Alzheimer DiseasePhase IICompletedPilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEGJan 30, 2020―
Ct1812Mild To Moderate Alzheimer's DiseasePhase IICompletedA Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.Apr 10, 2018―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Cognition Therapeutics, Inc. (CGTX) have in its pipeline
Cognition Therapeutics CGTX is currently developing the following drugs: Active Comparator Ct1812, Ct1812. These drug candidates are in various stages of clinical development as the company works toward FDA approval.